Compassion, clear communication, empathy and more—Samantha C. Shapiro, MD, provides practical advice on how to connect with your patients during appointments.
Rheumatologists must do some detective work into a patient’s signs and symptoms when considering a psoriatic arthritis diagnosis, according to Philip J. Mease, MD, MACR
Research from Baker et al. demonstrated a strong association between the presence of metabolic syndrome and lower response rates to advanced therapies in patients with RA.
These events will provide a critical opportunity for patients, caregivers, patient organizations, clinicians and researchers to offer input on the drugs selected for the second cycle of negotiations.
RheumPAC contributions enable the ACR to educate key legislators and their staff about the critical issues rheumatologists and rheumatology care team members face.
The new chair of the ACR’s Pediatric Rheumatology Committee, Ekemini A. Ogbu, MD, MSc, FAAP, describes how helping children and families navigate complex care brings a sense of fulfillment, purpose and “just joy.”
As the new administration enacts policies that impact you and the care you provide to your patients, RheumPAC is working to inform key lawmakers of the downstream effects of these unilateral actions. Learn more about RheumPAC’s role in the ACR’s advocacy efforts.
The FDA is reviewing supplemental biologics license applications for guselkumab to treat children with juvenile psoriatic arthritis and moderate to severe plaque psoriasis.
Luke Barré, MD, MPH, RhMSUS, has been elected to the American Medical Association’s Relative Value Update Committee. He is the second rheumatologist to hold the seat in recent years and will ensure representation of the specialty during valuation of physician services.